NCT03553836 · OUTCOME

Overall Survival (OS)

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) · Source last updated 2024-11-29

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to ~15 years

What was measured

OS will be defined as the time from randomization to death due to any cause. OS will be reported for randomized participants.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2033-10
denom Units Selected: Participants
description: OS will be defined as the time from randomization to death due to any cause. OS will be reported for randomized participants.
reporting Status: NOT_POSTED
time Frame: Up to ~15 years
title: Overall Survival (OS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice